Cresset Asset Management LLC Invests $771,000 in Stoke Therapeutics, Inc. $STOK

Cresset Asset Management LLC purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 32,795 shares of the company’s stock, valued at approximately $771,000. Cresset Asset Management LLC owned approximately 0.06% of Stoke Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock valued at $162,000 after purchasing an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Stoke Therapeutics by 21.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after purchasing an additional 293,072 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Stoke Therapeutics by 125.2% in the 1st quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after purchasing an additional 15,001 shares in the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Stoke Therapeutics in the 2nd quarter valued at $224,000. Finally, Aviva PLC bought a new position in shares of Stoke Therapeutics in the 2nd quarter valued at $499,000.

Stoke Therapeutics Price Performance

STOK opened at $38.35 on Wednesday. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $40.22. The company’s 50 day moving average price is $32.44 and its two-hundred day moving average price is $29.35. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of 57.24 and a beta of 1.07.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Wedbush lifted their target price on Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research report on Monday, January 12th. Guggenheim initiated coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They set a “buy” rating and a $60.00 target price for the company. UBS Group set a $50.00 target price on shares of Stoke Therapeutics in a report on Monday, December 15th. Finally, Canaccord Genuity Group raised their price target on shares of Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $39.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.